Timely levodopa (LD) administration prolongs survival in Parkinson's disease

A. H. Rajput, Ryan J. Uitti, Alex H. Rajput, Kenneth P. Offord

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Levodopa (LD) is the most effective drug for symptomatic control of Parkinsonism (PS). As prolonged LD therapy leads to response failure; is associated with adverse effects; may accelerate disease process, and its impact on life expectancy is controversial, delaying LD use has been recommended. We studied 934 PS cases including 859 Parkinson's disease (PD) patients over twenty-two years (1968-1990) to identify: (i) survival change coincident with widespread LD use and (ii) the critical level of disease severity when LD influences survival. Survival was measured from the date of first assessment until the last evaluation for a cumulative 3563 person- years of follow-up and compared with that expected in the general population of the same age, sex and year of birth. A Cox regression model was used to identify independent clinical predictors of survival. The observed to expected survival was reduced significantly in PS. Dementia and advanced disability at initial assessment and the final non-PD diagnosis, each was independently associated with poor survival. Survival improved significantly coincident with the widespread unrestricted access to LD (p = 0.024 -< 0.001) compared to pre-levodopa era cases. Life expectancy was longest in the more recent non-demented PD cases. When the major disease and treatment related factors were considered the timely use of levodopa in the recent cases resulted in improved survival compared to the earlier cases who received LD later in the course of illness. When LD naive cases were considered, survival was significantly reduced if the drug was delayed until Stage 3 Hoehn and Yahr, but not so if the patients remained untreated during Stages 1 and 2 Hoehn and Yahr [1]. Life expectancy in PD has increased significantly since the widespread use of LD. This benefit is evident only if LD therapy is initiated before the patient reaches Stage 2.5 disability [2].

Original languageEnglish (US)
Pages (from-to)159-165
Number of pages7
JournalParkinsonism and Related Disorders
Volume3
Issue number3
DOIs
StatePublished - Nov 1997

Fingerprint

Levodopa
Parkinson Disease
Survival
Life Expectancy
Parkinsonian Disorders
Secondary Parkinson Disease
Drug and Narcotic Control
Proportional Hazards Models
Dementia
Therapeutics
Parturition

ASJC Scopus subject areas

  • Aging
  • Clinical Neurology
  • Neurology

Cite this

Timely levodopa (LD) administration prolongs survival in Parkinson's disease. / Rajput, A. H.; Uitti, Ryan J.; Rajput, Alex H.; Offord, Kenneth P.

In: Parkinsonism and Related Disorders, Vol. 3, No. 3, 11.1997, p. 159-165.

Research output: Contribution to journalArticle

Rajput, A. H. ; Uitti, Ryan J. ; Rajput, Alex H. ; Offord, Kenneth P. / Timely levodopa (LD) administration prolongs survival in Parkinson's disease. In: Parkinsonism and Related Disorders. 1997 ; Vol. 3, No. 3. pp. 159-165.
@article{cf261a2d5a864952afe3b0168a8ff1f6,
title = "Timely levodopa (LD) administration prolongs survival in Parkinson's disease",
abstract = "Levodopa (LD) is the most effective drug for symptomatic control of Parkinsonism (PS). As prolonged LD therapy leads to response failure; is associated with adverse effects; may accelerate disease process, and its impact on life expectancy is controversial, delaying LD use has been recommended. We studied 934 PS cases including 859 Parkinson's disease (PD) patients over twenty-two years (1968-1990) to identify: (i) survival change coincident with widespread LD use and (ii) the critical level of disease severity when LD influences survival. Survival was measured from the date of first assessment until the last evaluation for a cumulative 3563 person- years of follow-up and compared with that expected in the general population of the same age, sex and year of birth. A Cox regression model was used to identify independent clinical predictors of survival. The observed to expected survival was reduced significantly in PS. Dementia and advanced disability at initial assessment and the final non-PD diagnosis, each was independently associated with poor survival. Survival improved significantly coincident with the widespread unrestricted access to LD (p = 0.024 -< 0.001) compared to pre-levodopa era cases. Life expectancy was longest in the more recent non-demented PD cases. When the major disease and treatment related factors were considered the timely use of levodopa in the recent cases resulted in improved survival compared to the earlier cases who received LD later in the course of illness. When LD naive cases were considered, survival was significantly reduced if the drug was delayed until Stage 3 Hoehn and Yahr, but not so if the patients remained untreated during Stages 1 and 2 Hoehn and Yahr [1]. Life expectancy in PD has increased significantly since the widespread use of LD. This benefit is evident only if LD therapy is initiated before the patient reaches Stage 2.5 disability [2].",
author = "Rajput, {A. H.} and Uitti, {Ryan J.} and Rajput, {Alex H.} and Offord, {Kenneth P.}",
year = "1997",
month = "11",
doi = "10.1016/S1353-8020(97)00030-8",
language = "English (US)",
volume = "3",
pages = "159--165",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Timely levodopa (LD) administration prolongs survival in Parkinson's disease

AU - Rajput, A. H.

AU - Uitti, Ryan J.

AU - Rajput, Alex H.

AU - Offord, Kenneth P.

PY - 1997/11

Y1 - 1997/11

N2 - Levodopa (LD) is the most effective drug for symptomatic control of Parkinsonism (PS). As prolonged LD therapy leads to response failure; is associated with adverse effects; may accelerate disease process, and its impact on life expectancy is controversial, delaying LD use has been recommended. We studied 934 PS cases including 859 Parkinson's disease (PD) patients over twenty-two years (1968-1990) to identify: (i) survival change coincident with widespread LD use and (ii) the critical level of disease severity when LD influences survival. Survival was measured from the date of first assessment until the last evaluation for a cumulative 3563 person- years of follow-up and compared with that expected in the general population of the same age, sex and year of birth. A Cox regression model was used to identify independent clinical predictors of survival. The observed to expected survival was reduced significantly in PS. Dementia and advanced disability at initial assessment and the final non-PD diagnosis, each was independently associated with poor survival. Survival improved significantly coincident with the widespread unrestricted access to LD (p = 0.024 -< 0.001) compared to pre-levodopa era cases. Life expectancy was longest in the more recent non-demented PD cases. When the major disease and treatment related factors were considered the timely use of levodopa in the recent cases resulted in improved survival compared to the earlier cases who received LD later in the course of illness. When LD naive cases were considered, survival was significantly reduced if the drug was delayed until Stage 3 Hoehn and Yahr, but not so if the patients remained untreated during Stages 1 and 2 Hoehn and Yahr [1]. Life expectancy in PD has increased significantly since the widespread use of LD. This benefit is evident only if LD therapy is initiated before the patient reaches Stage 2.5 disability [2].

AB - Levodopa (LD) is the most effective drug for symptomatic control of Parkinsonism (PS). As prolonged LD therapy leads to response failure; is associated with adverse effects; may accelerate disease process, and its impact on life expectancy is controversial, delaying LD use has been recommended. We studied 934 PS cases including 859 Parkinson's disease (PD) patients over twenty-two years (1968-1990) to identify: (i) survival change coincident with widespread LD use and (ii) the critical level of disease severity when LD influences survival. Survival was measured from the date of first assessment until the last evaluation for a cumulative 3563 person- years of follow-up and compared with that expected in the general population of the same age, sex and year of birth. A Cox regression model was used to identify independent clinical predictors of survival. The observed to expected survival was reduced significantly in PS. Dementia and advanced disability at initial assessment and the final non-PD diagnosis, each was independently associated with poor survival. Survival improved significantly coincident with the widespread unrestricted access to LD (p = 0.024 -< 0.001) compared to pre-levodopa era cases. Life expectancy was longest in the more recent non-demented PD cases. When the major disease and treatment related factors were considered the timely use of levodopa in the recent cases resulted in improved survival compared to the earlier cases who received LD later in the course of illness. When LD naive cases were considered, survival was significantly reduced if the drug was delayed until Stage 3 Hoehn and Yahr, but not so if the patients remained untreated during Stages 1 and 2 Hoehn and Yahr [1]. Life expectancy in PD has increased significantly since the widespread use of LD. This benefit is evident only if LD therapy is initiated before the patient reaches Stage 2.5 disability [2].

UR - http://www.scopus.com/inward/record.url?scp=0031443024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031443024&partnerID=8YFLogxK

U2 - 10.1016/S1353-8020(97)00030-8

DO - 10.1016/S1353-8020(97)00030-8

M3 - Article

C2 - 18591070

AN - SCOPUS:0031443024

VL - 3

SP - 159

EP - 165

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

IS - 3

ER -